| LIQUIDIA CORP. DL-,001 |
| USA |
| Gesundheit |
| US53635D2027 / A2JRNS |
| LT4 (Frankfurt) / LQDA (NASDAQ) |
| FRA:LT4, ETR:LT4, LT4:GR, NASDAQ:LQDA |
| - |
| https://liquidia.com/ |
|
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of innovative therapies. Primarily engaged in the healthcare sector, Liquidia employs PRINT technol..
>Volltext.. |
| 2321.47 Mio. EUR |
| 2357.28 Mio. EUR |
| 59.7 Mio. EUR |
| -91.03 Mio. EUR |
| -105.09 Mio. EUR |
| -1.23 EUR |
| 171.79 Mio. EUR |
| 135.84 Mio. EUR |
| -86.89 Mio. EUR |
| 1.53 |
| 320.72% |
| 3.23% |
| - |
| - |
| - |
| LIQUIDIA |
| 04.03.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|